Navigation Links
Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

improved radial strength, which is intended to maintain vessel expansion so blood can flow through.

"Not only is the ABSORB trial beginning to show that bioabsorbable technology, when applied to coronary stents, can work -- it can also provides a foundation for future interventional medical innovation," said John M. Capek, Ph.D., senior vice president, Abbott Vascular. "Five years ago, the technology and 'know-how' to make a fully functioning bioabsorbable drug eluting stent didn't exist, but every success in the ABSORB trial brings us one step closer to providing this important new treatment option to physicians for their patients."

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label) study designed to enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. Key endpoints of the study include assessments of safety; MACE and stent thrombosis (blood clot formation) rates at 30, 180 and 270 days, with an annual follow-up for up to five years, and successful deployment of the bioabsorbable drug eluting stent. Other key endpoints of the study include follow-up measurements assessed by X-ray angiography, intravascular ultrasound (IVUS), and state-of-the-art imaging modalities at 180 days and two years.

In March, six-month results from the first 30 patients in the ABSORB trial were presented at the of Cardiology conference, demonstrating no stent thrombosis and a low (3.3 percent, one patient) of Major Adverse Cardiac Events (MACE), such as heart attack or repeat interventional medical treatment.

For images of Abbott's investigational bioabsorbable stent and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses.
'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:4/30/2015)... WOODBRIDGE, ON , April 30, 2015 /PRNewswire/ ... a specialty pharmaceutical company with a focus on ... health, announced its operational highlights and financial results ...  All dollar amounts referenced herein are in Canadian ... in 2014 have been significant, with the right ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
(Date:4/30/2015)... Calif. , April 30, 2015  IRIDEX Corporation ... release its first quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, May ... quarter and other business developments. Interested parties ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... ProStrakan Group plc (LSE: PSK) today announced the ... the first rapidly-disintegrating tablet placed under the tongue for ... (F.D.A.) approved ABSTRAL, an opioid analgesic, in January 2011 ... patients, 18 years of age or older, ...
... Daiichi Sankyo, Inc. (DSI) announced today that John P. ... Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is ... the past 14 years. "John,s experiences within ... him well for his new role and responsibility," said Joseph ...
Cached Medicine Technology:ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 2ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 3ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 4ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 5ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 6ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 7John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. 2
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 It’s a pattern that won’t ... strikes anywhere on this planet, cyber scammers will immediately ... compassion for their own personal gain. And on ... Team) issued an alert titled “Nepal Earthquake Disaster ... citing the earthquake in Nepal. The scam emails may ...
(Date:5/2/2015)... Ohio (PRWEB) May 02, 2015 On ... Liverpool City Hospital (ELCH) gathered to celebrate improvements in ... River Valley Health Partners (RVHP), had zero acquired ventilator ... urinary catheter associated infections. ELCH was also recently named ... The management team at ELCH credited the teamwork of ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
(Date:5/1/2015)... Caicos Islands, BWI (PRWEB) May 02, 2015 ... website! It is http://www.thevenetiangracebay.com , and it ... it incorporates the stunning white and attractive turquoise hues ... study of Google, sixty seven percent of leisure travelers ... study showed that smartphones were used in the planning ...
Breaking Medicine News(10 mins):Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2
... , , FRIDAY, May 23 (HealthDay News) -- Patients with ... a few years of diagnosis may finally have some ... of the drug pirfenidone improved the lung function and ... idiopathic pulmonary fibrosis (IPF). , "Patients look to any ...
... When Jon Ziefert and Steve Smith were,recovering from ... food gift baskets. "Some were healthy but most ... ... was highly,perishable. So they had to give most of ... and other high-sugar, high-fat foods simply had no,place in ...
... Jorge Alan Rodriguez,Sanchez, 32, was indicted by ... distribute controlled substances through the operation of an,illegal ... Alice S. Fisher and U.S. Attorney Patrick L. ... Sanchez is also charged with four counts ...
... Follow Along Online, WICHITA, Kan., May 22 ... of the world -- Mount Everest -- that was ... another,mountain? How about climb to the highest point of ... 50 days or less., (Photo: http://www.newscom.com/cgi-bin/prnh/20080522/AQTH080LOGO ), ...
... HOUSTON, May 22 The 39th gathering of the ... a 60-member West,African choir to help celebrate the success ... between Methodists in Texas and,Cote d,Ivoire (Ivory Coast). The ... 25-28., A proclamation reading and signing on May ...
... generated by Shahin Rafii and colleagues, at Weill Medical College ... cancer cells and mice, have shed doubt on the recently ... colon cancer stem cells a term given to the ... thought to be able to give rise to a new ...
Cached Medicine News:Health News:Drug for Deadly Lung Disease Shows Promise 2Health News:Drug for Deadly Lung Disease Shows Promise 3Health News:Cancer Survivors Develop Healthy Food Gift Business 2Health News:California Man Indicted For Conspiracy In Operating Internet Pharmacy 2Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 2Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 3Health News:Local Methodists Host West African Choir, South African Leader at Historic Conference 2
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: